OtherInvestigational

Cortistatin

A neuropeptide related to somatostatin that has been studied for anti-inflammatory, neuroendocrine, and cardiovascular effects.

NeuropeptideImmuneInflammationInvestigational

Also referenced as: CST

Also appears in: Hormone · Immune

Public product evidenceSearch the public certificate ledger for this compoundNo exact compound records are currently indexed under this profile name.
Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area
Other research areas

Primary research area: Other. Also surfaces under Hormone · Immune for browsing and discovery.

Aliases
1

CST

Signal depth
Medium

No FDA label signal · 741 trials · 8168 PubMed results

Preclinical
Research evidence

Current evidence for Cortistatin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Cortistatin has 2 name-matched clinical trials (highest phase: no phased trial) and 8170 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

Human data
Human (non-phased)
Trial quality
Observational
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
TrialValidation of the Consecutive-Letter Substitution Task (CST)NAIDEA Study Cognitive Stimulation Therapy (CST) Trial in NigeriaArthritis Care & Research · 465 citationsMeasures of physical performance assessments: Self‐Paced Walk Test (SPWT), Stair Climb Test (SCT), Six‐Minute Walk Test (6MWT), Chair Stand Test (CST), Timed Up & Go (TUG), Sock Test, Lift and Carry Test (LCT), and Car TaskNature · 450 citations53BP1–RIF1–shieldin counteracts DSB resection through CST- and Polα-dependent fill-inNature · 366 citationsThe human CST complex is a terminator of telomerase activityJournal ArticleHeterogeneous Interface Engineering Enabled ZnO/C Hybrid Aerogels for High-Performance Radar-Infrared Compatible Stealth.
Evidence history
  1. 2026-09-01Promising→PreclinicalBand Promising → Preclinical; -15 trials
  2. 2026-08-28Preclinical→PromisingBand Preclinical → Promising; -15 trials; +2 PubMed
  3. 2026-08-25Promising→PreclinicalBand Promising → Preclinical; +22 trials
  4. 2026-08-22Preclinical→PromisingBand Preclinical → Promising; -14 trials
  5. 2026-08-18Promising→PreclinicalBand Promising → Preclinical; +8 trials; +1 PubMed
  6. 2026-08-15Preclinical→PromisingBand Preclinical → Promising; +7 trials; +3 PubMed
  7. 2026-07-30Promising→PreclinicalBand Promising → Preclinical; -22 trials; +2 PubMed
  8. 2026-07-29Preclinical→PromisingBand Preclinical → Promising; +15 trials; +10 PubMed
  9. 2026-07-21Promising→PreclinicalBand Promising → Preclinical; -15 trials
  10. 2026-07-17Preclinical→PromisingBand Preclinical → Promising; +15 trials
  11. 2026-07-09PreclinicalFirst graded

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What cortistatin is

Cortistatin is a neuropeptide related to somatostatin with research relevance in inflammation, neuroendocrine signaling, and cardiovascular biology.

Why it matters

It is a good example of a peptide that is scientifically interesting and biologically rich even though it is not a mainstream vendor-market name.

Regulatory context

Cortistatin is not FDA approved as a therapeutic peptide in the United States.

Practical reading note

Adding peptides like cortistatin helps keep the library from becoming only a catalog of the internet’s loudest compounds.